Literature DB >> 32168262

Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.

Harpreet Singh1, Geetanjali Arora1, Brusabhanu Nayak2, Akshima Sharma1, Geetika Singh3, Kalpana Kumari3, Suman Jana4, Chetan Patel1, Anil Kumar Pandey1, Amlesh Seth2, Rakesh Kumar1.   

Abstract

OBJECTIVE: The primary objective of the study was to evaluate the correlation between semi-quantitative F-18 FDG PET parameters and renal cell carcinoma (RCC) grade and its role in predicting the histopathological grade in RCC. The secondary objective was to evaluate the role of forced diuresis in improving the diagnostic accuracy of F-18 FDG for RCC.
METHODS: Thirty-three patients with radiologically proven RCC were included in the study. All patients underwent PET/CT on a dedicated PET/CT scanner (Biograph mCT; Siemens Medical Solutions, Erlangen, Germany) 45-60 min post-injection F-18-FDG. Patients were then injected 1 mg/kg body weight furosemide (upto 40 mg) and regional PET/CT images of abdomen were acquired after 2 h. For both baseline and post-diuretic F-18-FDG PET/CT scans, maximum standardized uptake value for tumor (SUVmax), mean SUV for tumor, metabolic tumor volume (MTV), tumor-to-liver (T/L) and tumor-to-kidney ratio (T/K) were calculated. Histopathology findings were considered as the reference standard. To assess the incremental value of diuresis in scan interpretation, visual analysis of scans was done.
RESULTS: Of 33 patients, histopathology grading was available for comparison with metabolic tumor markers in all except four. Of 29 patients (mean age = 51.89 ± 13.54 years), 20 patients had clear cell (cc) type while rest had non-cc RCC. Difference between the mean values among the categories was insignificant for all parameters except T/K. Fuhrman grading was obtained in 25 patients (17 low and eight high). SUVmax, MTV and T/L were found to be significantly different between low and high grade patients. Significantly strong positive correlation was observed between Furhman grades and tumor metabolism (r ≥ 0.5). No significant difference was observed between baseline and post-diuretic scan in any of the patients.
CONCLUSION: Semi-quantitative F-18 FDG PET parameters (SUVmax, MTV and T/L) were found to be significantly correlated with Fuhrman grade in patients with RCC and are important markers for differentiation between low- and high-grade tumors. Furthermore, forced diuresis had no incremental value in characterization of primary RCC lesions.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32168262     DOI: 10.1097/MNM.0000000000001169

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  4 in total

1.  2-[18F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma.

Authors:  Yanyan Zhao; Caixia Wu; Wei Li; Xueqi Chen; Ziao Li; Xuhe Liao; Yonggang Cui; Guangyu Zhao; Meng Liu; Zhanli Fu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-19       Impact factor: 9.236

2.  18F-FDG texture analysis predicts the pathological Fuhrman nuclear grade of clear cell renal cell carcinoma.

Authors:  Linhan Zhang; Hongyue Zhao; Huijie Jiang; Hong Zhao; Wei Han; Mengjiao Wang; Peng Fu
Journal:  Abdom Radiol (NY)       Date:  2021-08-28

3.  The effects of baicalin on piglets challenged with Glaesserella parasuis.

Authors:  Shulin Fu; Ronghua Yin; Sanling Zuo; Jun Liu; Yunfei Zhang; Ling Guo; Yinsheng Qiu; Chun Ye; Yu Liu; Zhongyuan Wu; Yongqing Hou; Chien-An Andy Hu
Journal:  Vet Res       Date:  2020-08-14       Impact factor: 3.683

4.  Metabolic tumour volume on 18F-FDG PET/CT predicts extended pathological T stages in patients with renal cell carcinoma at staging.

Authors:  Dongwoo Kim; Narae Lee; Woong Kyu Han; Mijin Yun; Suk Hyun Lee; Hyun Jeong Kim; Hye-Suk Hong; Jee Soo Park; Nam-Hoon Cho; Young Deuk Choi; Won Sik Ham; Seung Hwan Lee
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.